Future oncology最新文献_第5页

Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy. 基于permaar的心理干预及预测性护理在恶性肿瘤患者化疗后的效果。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1080/14796694.2025.2497257

Xiuying Hu, Qiuyue Li, Liying Tang

{"title":"Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy.","authors":"Xiuying Hu, Qiuyue Li, Liying Tang","doi":"10.1080/14796694.2025.2497257","DOIUrl":"10.1080/14796694.2025.2497257","url":null,"abstract":"Background: Alleviating the toxic and adverse reactions associated with chemotherapy is crucial for improving patient outcomes. This study aimed to assess the impacts of positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) model-based psychological interventions and predictive chemotherapy reaction nursing on patients with malignant tumors following chemotherapy.Research design and methods: The control group (n = 43) received conventional care, while the observation group (n = 43) received psychological intervention based on PERMA model alongside predictive nursing care. Chemotherapy-induced toxicity and side effects, fatigue levels, coping mode, psychological status, and quality of life were assessed.Results: Compared to the control group, the observation group exhibited a lower incidence of gastrointestinal adverse reactions, myelosuppression, alopecia, and oral ulcers (p < 0.05), reduced behavioral, cognitive, somatic, and emotional fatigue (p < 0.001), lower scores in avoidance and yielding coping styles (p < 0.001), higher scores in confrontation coding mode (p = 0.056), improved quality of life, and better outcomes in anxiety, depression, and overall psychological state of patients (p < 0.001).Conclusion: PERMA model-based psychological interventions and predictive chemotherapy reaction nursing interventions effectively reduce the incidence of chemotherapy-induced toxicity, alleviate fatigue, enhance quality of life, and improve psychological well-being in cancer patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1639-1645"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access. 克服障碍的先进生物分子技术，告知治疗实体瘤：路线图获取。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/14796694.2025.2501523

Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger

{"title":"Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.","authors":"Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger","doi":"10.1080/14796694.2025.2501523","DOIUrl":"10.1080/14796694.2025.2501523","url":null,"abstract":"The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a \"roadmap to access\" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1745-1752"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). nivolumab再给药治疗晚期胃癌（NIVO RETURNS）的多中心、前瞻性、观察性研究。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/14796694.2025.2500918

Hiroyuki Kodama, Yukiya Narita, Michio Nakamura, Masanobu Takahashi, Takuro Mizukami, Takayuki Ando, Seiichiro Mitani, Azusa Komori, Ayumu Hosokawa, Toshikazu Moriwaki, Keiji Sugiyama, Masataka Taguri, Shunichiro Orihara, Hiroshi Kagamu, Toshifumi Yamaguchi, Hiroki Nishikawa, Kei Muro

{"title":"A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS).","authors":"Hiroyuki Kodama, Yukiya Narita, Michio Nakamura, Masanobu Takahashi, Takuro Mizukami, Takayuki Ando, Seiichiro Mitani, Azusa Komori, Ayumu Hosokawa, Toshikazu Moriwaki, Keiji Sugiyama, Masataka Taguri, Shunichiro Orihara, Hiroshi Kagamu, Toshifumi Yamaguchi, Hiroki Nishikawa, Kei Muro","doi":"10.1080/14796694.2025.2500918","DOIUrl":"10.1080/14796694.2025.2500918","url":null,"abstract":"Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC.Clinical trial registration: UMIN000050515, UMIN000051044.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1753-1759"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked. 优化局部晚期直肠癌的新辅助治疗：风险分层不应被忽视。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-22 DOI: 10.1080/14796694.2025.2507560

Jingyi Liu, Ximo Xu, Hao Zhong, Mengqin Yu, Naijipu Abuduaini, Abe Fingerhut, Zhenghao Cai, Bo Feng

引用次数: 0

Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis. 预后营养指数在淋巴瘤相关噬血细胞性淋巴组织细胞增多症患者中的预后作用。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-22 DOI: 10.1080/14796694.2025.2507565

Na Li, You Feng, Liqun Zou

{"title":"Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.","authors":"Na Li, You Feng, Liqun Zou","doi":"10.1080/14796694.2025.2507565","DOIUrl":"10.1080/14796694.2025.2507565","url":null,"abstract":"Aims: Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) is a rare and life-threatening disorder. While the prognostic nutritional index (PNI) has been recognized as an independent prognostic indicator in lymphoma studies, its specific role in LA-HLH has not yet been reported.Methods: We retrospectively examined clinical characteristics and prognostic factors from 124 LA-HLH patients.Results: 23 patients (18.5%) had B-cell lymphoma-associated HLH (B-LA-HLH), and 101 cases presented with T or natural killer (NK)-cell lymphoma-associated HLH (T/NK-LA-HLH). The median survival time for the entire group was two months, with T/NK-LA-HLH and B-LA-HLH showing median survival times of 1.6 months and 5.0 months, respectively, post-HLH diagnosis. The optimal threshold for the prognostic nutritional index (PNI) was 35.5. Analysis of prognostic factors indicated that the HLH onset at lymphoma relapse and a PNI below 35.5 were independent predictors of inferior overall survival. Patients with a PNI below 35.5 had a significantly shorter estimated survival duration than those with a PNI of 35.5 or higher (p = 0.003).Conclusions: The onset of HLH at lymphoma relapse and a low PNI may be considered adverse prognostic indicators for LA-HLH, potentially aiding in risk stratification and informing clinical decisions.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1879-1886"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy. 意大利含西妥昔单抗治疗头颈部鳞状细胞癌的成本-效果

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-18 DOI: 10.1080/14796694.2025.2503667

Philipp Ivanyi, Ash Bullement, Andrea Botticelli, Francesco Perri, Giorgio L Colombo, Viviana Annibali, Anita Gandola, Jaesh Naik, Michael Schlichting, Chris P Pescott

{"title":"Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.","authors":"Philipp Ivanyi, Ash Bullement, Andrea Botticelli, Francesco Perri, Giorgio L Colombo, Viviana Annibali, Anita Gandola, Jaesh Naik, Michael Schlichting, Chris P Pescott","doi":"10.1080/14796694.2025.2503667","DOIUrl":"10.1080/14796694.2025.2503667","url":null,"abstract":"Aims: To investigate the differences in clinical outcomes and costs for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) with a combined positive score (CPS) of 1-19, with pembrolizumab ± chemotherapy or a cetuximab-containing regimen (CCR) in Italy.Methods: A naïve indirect treatment comparison was conducted, and outcomes were incorporated into a newly developed cost-utility model. Inputs were derived from clinical trials, technology appraisal reports, and published literature. Scenario analyses were undertaken to explore key areas of uncertainty.Results: Across the comparisons of pembrolizumab ± chemotherapy versus CCRs, incremental life-years ranged from - 0.502 to 0.155, while incremental quality-adjusted life years (QALYs) ranged from - 0.379 to 0.085. In some scenarios, CCRs dominated pembrolizumab ± chemotherapy (i.e. more QALYs at lower costs). In others, CCRs yielded similar estimates of QALYs at lower costs.Conclusion: CCRs are likely to represent a comparable or more effective treatment option compared to pembrolizumab ± chemotherapy. Model results consistently demonstrated that CCRs are a cost-effective treatment strategy. CCRs remain a relevant treatment option for R/M SCCHN and a CPS of 1-19, for whom a targeted, patient-focused approach is warranted.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1779-1786"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study. 胃肠道间质瘤伴淋巴结转移的临床特征：一项回顾性单中心研究。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796694.2025.2499431

Xiaodan Guo, Shaoqing Huang, Shaohua Yang, Yanzhe Xia, Chunhui Wu, Shirong Cai, Yulong He, Xuefu Zhou, Xinhua Zhang

{"title":"Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study.","authors":"Xiaodan Guo, Shaoqing Huang, Shaohua Yang, Yanzhe Xia, Chunhui Wu, Shirong Cai, Yulong He, Xuefu Zhou, Xinhua Zhang","doi":"10.1080/14796694.2025.2499431","DOIUrl":"10.1080/14796694.2025.2499431","url":null,"abstract":"Background: Lymph node metastasis (LNM) of gastrointestinal stromal tumors (GISTs) rarely occurs, and lymphadenectomy is not routinely performed in GIST resection. To date, the relevant characteristics and prognosis of GIST patients with LNM are not well known.Methods: From January 2010 to December 2021, GIST patients who underwent lymph node resection were enrolled from a GIST referral center. All patients were divided into either the LN- group (GISTs without LNM) or the LN+ group (GISTs with LNM). The clinicopathological features and follow-up data were analyzed. Propensity score matching (PSM) was conducted to reduce bias caused by confounders.Results: Out of 1024 surgical patients, 198 patients (age, 52.23 ± 13.54 years; 56.6% males) underwent GIST resection with lymph node dissection for lymphadenopathy, and 17 patients had lymph node metastases (17/1024, 1.66%; 17/198, 8.59%). The LN+ group had a higher mitotic count (p = 0.012) and a higher proportion of distant metastasis (p < 0.001) than the LN- group. After PSM, 28 patients were included (18 in LN- group and 10 in LN+ group). The LN- group had both longer postoperative progression-free survival (PFS, not reached vs. 15.0 months, p = 0.002) and overall survival (OS) than the LN+ group, but the difference in OS was not statistically significant (not reached vs. 35.0 months, p = 0.069).Conclusions: The rate of LNM in GISTs is low. LNM may be a less common form of distant metastasis. Moreover, GIST with LNM has an unfavorable prognosis. Further studies are warranted to identify GISTs with lymph node involvement and the potential involved mechanism.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1655-1662"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients. 多米尼卡：多斯塔利单抗与化疗单独治疗一线mmr缺陷晚期子宫内膜癌患者

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796694.2025.2496133

François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre, Florence Joly

{"title":"DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.","authors":"François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre, Florence Joly","doi":"10.1080/14796694.2025.2496133","DOIUrl":"10.1080/14796694.2025.2496133","url":null,"abstract":"Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1613-1623"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma. 肿瘤浸润性淋巴细胞治疗黑色素瘤前减少剂量氟达拉滨和环磷酰胺淋巴细胞清除。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1080/14796694.2025.2498842

Muhammad Umair Mushtaq, Haitham Abdelhakim, Luke Selby, Moazzam Shahzad, Sunil H Abhyankar, Joseph P McGuirk, Gary C Doolittle

引用次数: 0

Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study. nivolumab和ipilimumab在转移性肾细胞癌中的实际疗效和安全性：波兰多中心研究

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-20 DOI: 10.1080/14796694.2025.2508138

Renata Pacholczak-Madej, Artur Drobniak, Łukasz Stokłosa, Aleksandra Grela-Wojewoda, Jacek Calik, Natalia Versuti Viegas, Daria Tusień-Małecka, Marek Szwiec, Jolanta Dobrzańska, Agnieszka Roman, Anna Bidas, Angelika Gawlik-Urban, Jerzy Walocha, Paweł Blecharz, Mirosława Puskulluoglu

{"title":"Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study.","authors":"Renata Pacholczak-Madej, Artur Drobniak, Łukasz Stokłosa, Aleksandra Grela-Wojewoda, Jacek Calik, Natalia Versuti Viegas, Daria Tusień-Małecka, Marek Szwiec, Jolanta Dobrzańska, Agnieszka Roman, Anna Bidas, Angelika Gawlik-Urban, Jerzy Walocha, Paweł Blecharz, Mirosława Puskulluoglu","doi":"10.1080/14796694.2025.2508138","DOIUrl":"10.1080/14796694.2025.2508138","url":null,"abstract":"Background: Nivolumab plus ipilimumab (NIVO+IPI) is a first-line treatment for metastatic renal cell carcinoma (mRCC) in intermediate- and poor-risk patients. Real-world evidence (RWE) studies are needed to validate its efficacy and safety in clinical practice.Methods: This multicenter retrospective study included 145 mRCC patients treated with NIVO+IPI at nine oncology centers in Poland between May 2022 and December 2024. Data on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and immune-related adverseevents (irAEs) were analyzed using Kaplan-Meier survival estimates and Cox proportional hazards models, with p-value <0.05 considered statistically significant.Results: With a limited median follow-up of 10.9 months, median PFS was 12.8 months (95% CI:7.0-18.6), and median OS was not reached. ORR and DCR were 34.5% and 66.2%,respectively. In intermediate-risk patients, ORR and DCR were higher than in poor-risk patients without statistical significance. IrAEs occurred in 61.4% of patients, with grade 3/4 irAEs in 25.5%. Karnofsky Performance Status < 80%, central nervous system metastases, and hepatic irAEs were associated with poorer survival in a multivariate analysis (p = 0.002).Conclusions: This study confirms the real-world efficacy and safety of NIVO+IPI in mRCC, demonstrating outcomes comparable to clinical trials.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1895-1904"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0